Elevation goes down on Claudin disaster
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
Elevation brings Synaffix on board in HER3
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
Claudin18.2 expression clouds Elevation's big reveal
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
ASCO-GU – Corbus throws its hat into the Nectin-4 ring
The biotech surges on data with its new oncology lead, so could it have a new Padcev on its hands?
ASCO 2023 – Behind Astellas comes Elevation
Elevation’s anti-Claudin18.2 antibody-drug conjugate generates some justified optimism, but Zai Lab’s zolbetuximab challenger is out of luck.
